Novocure Ltd reports results for the quarter ended in September 30 - Earnings Summary

• Novocure Ltd NVCR.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -46 cents. The mean expectation of seven analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -41 cents to -23 cents per share.

• Revenue rose 21.8% to $155.10 million from a year ago; analysts expected $143.95 million.

• Novocure Ltd's reported EPS for the quarter was a loss of 28 cents​.

• The company reported a quarterly loss of $30.57 million.

• Novocure Ltd shares had risen by 8.1% this quarter and gained 13.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Novocure Ltd is 28.00

This summary was machine generated from LSEG data October 30 at 03:20 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)